Susquehanna International Group, LLP Seelos Therapeutics, Inc. Call Options Transaction History

Susquehanna International Group, LLP

11 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q3 2023 Nov 14, 2023	BUY	$0.16 - $1.64 $880 - $9,020	5,500 Added 3.98%	143,800 $25,000
Q2 2023 Aug 11, 2023	BUY	$0.66 - $1.22 $25,080 - $46,360	38,000 Added 37.89%	138,300 $165,000
Q1 2023 May 16, 2023	SELL	$0.59 - $1.04 $31,447 - $55,432	-53,300 Reduced 34.7%	100,300 $69,000
Q4 2022 Feb 14, 2023	SELL	$0.66 - $259.46 $2,112 - $830,271	-3,200 Reduced 2.04%	153,600 $104,000
Q3 2022 Nov 14, 2022	SELL	$0.65 - $278.68 $137,085 - $58.8 Million	-210,900 Reduced 57.36%	156,800 $162,000
Q2 2022 Aug 15, 2022	BUY	$0.51 - $0.93 $9,792 - $17,856	19,200 Added 5.51%	367,700 $250,000
Q1 2022 May 16, 2022	BUY	$0.84 - $1.71 $52,248 - $106,362	62,200 Added 21.73%	348,500 $293,000
Q4 2021 Feb 14, 2022	BUY	$1.59 - $2.38 $170,766 - $255,612	107,400 Added 60.03%	286,300 $467,000
Q3 2021 Nov 15, 2021	SELL	$1.69 - $2.89 $69,121 - $118,201	-40,900 Reduced 18.61%	178,900 $431,000
Q2 2021 Aug 11, 2021	BUY	$2.64 - $6.32 $443,520 - $1.06 Million	168,000 Added 324.32%	219,800 $580,000
Q1 2021 May 17, 2021	BUY	$1.35 - $4.99 $69,930 - $258,482	51,800 New	51,800 $258,000

40.5K

Ticker SEEL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 106,691,000
Market Cap $117M
Description
Seelos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for the treatment of central nervous system, respiratory, and other disorders. The company's lead programs are SLS-002, an intranasal racemic ketamine for the treatment of acute suicidal ideation and behavior in...

Get notified when there are updates to the investment portfolio of Susquehanna International Group, LLP, based on Form 13F filings with the SEC.

Stay updated on Susquehanna International Group, LLP with notifications on news.